R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B
The main purpose of this study is to evaluate the safety and efficacy of R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell lymphoma and Follicular Lymphoma Grade 3B patients.
Diffuse Large B-cell Lymphoma|Follicular Lymphoma Grade 3B
DRUG: R-CEOP-70|DRUG: R-CEOP-90|DRUG: R-CHOP-50
progression free survival, 2 year
overall survival, 2 year|Response rate, 21 days as one cycle, Every 4 cycles during treatment and then every 3 months for 2 years|Safety as assessed using the CTCAE, 21 days as one cycle, Days 1 of each course and then every 3 months for 2 years
The study aims to evaluate the safety and efficacy of R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell lymphoma and Follicular Lymphoma Grade 3B patients.